SCOPUS 정보 검색 플랫폼

Volumn 36, Issue 1, 2012, Pages 11-15

Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level;Evaluación retrospectiva de la efectividad y seguridad de cinacalcet para el tratamiento de hiperparatiroidismo secundario dependiendo del valor basal de paratohormona intacta

(2) Mercadal Orfila, G a Blasco Mascaro I a

a Hospital Mateu Orfila (Spain)

Author keywords

Cinacalcet; Dialysis; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS;

ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HORMONE BLOOD LEVEL; HUMAN; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; CALCIMIMETIC AGENTS; DRUG MONITORING; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; PARATHYROID HORMONE; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RETROSPECTIVE STUDIES;

EID: 84857373609 PISSN: 11306343 EISSN: 21718695 Source Type: Journal
DOI: 10.1016/j.farma.2010.10.008 Document Type: Article

Times cited : (3)

References (12)

1
- 69249134725
- Sociedad Española de Nefrología
- Sociedad Española de Nefrología. Recomendaciones de la Sociedad Española de Nefrología para el manejo de las alteraciones del metabolismo óseo-mineral en los pacientes con enfermedad renal crónica [consultado 24/04/2010]. Disponible en: http://www.senefro.org/ modules.php?name=webstructure&idwebstructure=4182008
- Recomendaciones de la Sociedad Española de Nefrología Para El Manejo de Las Alteraciones Del Metabolismo Óseo-mineral en Los Pacientes Con Enfermedad Renal Crónica [Consultado 24/04/2010]

2
- 3543139492
- Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
- DOI 10.1097/01.ASN.0000133041.27682.A2
- G. Block, P. Klassen, J. Lazarus, N. Ofsthun, E. Lowrie, and G. Chertow Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2004 2208 2218 (Pubitemid 39031360)
- (2004) Journal of the American Society of Nephrology , vol.15 , Issue.8 , pp. 2208-2218
- Block, G.A.¹ Klassen, P.S.² Lazarus, J.M.³ Ofsthun, N.⁴ Lowrie, E.G.⁵ Chertow, G.M.⁶

3
- 18144402703
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study
- DOI 10.1111/j.1523-1755.2005.00185.x
- E. Young, J. Albert, S. Satayathum, D. Goodkin, R. Pisoni, and T. Akiba Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study Kidney Int 67 2005 1179 1187 (Pubitemid 41623345)
- (2005) Kidney International , vol.67 , Issue.3 , pp. 1179-1187
- Young, E.W.¹ Albert, J.M.² Satayathum, S.³ Goodkin, D.A.⁴ Pisoni, R.L.⁵ Akiba, T.⁶ Akizawa, T.⁷ Kurokawa, K.⁸ Bommer, J.⁹ Piera, L.¹⁰ Port, F.K.¹¹

4
- 84857374044
- NICE technology appraisal guidance 117
- NICE technology appraisal guidance 117. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance dialysis therapy [consultado 14/03/2010]. Disponible en: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=116072007
- Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Patients with End Stage Renal Disease on Maintenance Dialysis Therapy [Consultado 14/03/2010]

5
- 68949114585
- KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
- Group KDIGOKC-MW
- Group KDIGOKC-MW KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl 113 2009 S1 130
- (2009) Kidney Int Suppl , vol.113 , pp. 1-130

6
- 84857357407
- Cinacalcet
- Cinacalcet. Informe EPAR Agencia Europea del Medicamento (EMEA) [consultado 24/04/2010]. Disponible en: http://www.ema.europa.eu/humandocs/PDFs/ EPAR/mimpara/emea-combined-h570es.pdf2004
- Informe EPAR Agencia Europea Del Medicamento (EMEA) [Consultado 24/04/2010]

7
- 29144431716
- Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism
- DOI 10.1111/j.1523-1755.2005.00596.x, PII 4494782
- J. Cunningham, M. Danese, K. Olson, P. Klassen, and G.M. Chertow Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney International 68 2005 1793 1800 (Pubitemid 43169924)
- (2005) Kidney International , vol.68 , Issue.4 , pp. 1793-1800
- Cunningham, J.¹ Danese, M.² Olson, K.³ Klassen, P.⁴ Chertow, G.M.⁵

8
- 20544460709
- Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study
- DOI 10.1681/ASN.2004060512
- J.S. Lindberg, B. Culleton, G. Wong, M.F. Borah, R.V. Clark, and W.B. Shapiro Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in Hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 2005 800 807 (Pubitemid 41725117)
- (2005) Journal of the American Society of Nephrology , vol.16 , Issue.3 , pp. 800-807
- Lindberg, J.S.¹ Culleton, B.² Wong, G.³ Borah, M.F.⁴ Clark, R.V.⁵ Shapiro, W.B.⁶ Roger, S.D.⁷ Husserl, F.E.⁸ Klassen, P.S.⁹ Guo, M.D.¹⁰ Albizem, M.B.¹¹ Coburn, J.W.¹²

9
- 11144353767
- Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
- DOI 10.1056/NEJMoa031633
- G.A. Block, K.J. Martin, A.L.M. de Francisco, S.A. Turner, M.M. Avram, and M.G. Suranyi Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 2004 1516 1525 (Pubitemid 38477776)
- (2004) New England Journal of Medicine , vol.350 , Issue.15 , pp. 1516-1525
- Block, G.A.¹ Martin, K.J.² De Francisco, A.L.M.³ Turner, S.A.⁴ Avram, M.M.⁵ Suranyi, M.G.⁶ Hercz, G.⁷ Cunningham, J.⁸ Abu-Alfa, A.K.⁹ Messa, P.¹⁰ Coyne, D.W.¹¹ Locatelli, F.¹² Cohen, R.M.¹³ Evenepoel, P.¹⁴ Moe, S.M.¹⁵ Fournier, A.¹⁶ Braun, J.¹⁷ McCary, L.C.¹⁸ Zani, V.J.¹⁹ Olson, K.A.²⁰ Drueke, T.B.²¹ Goodman, W.G.²² more..

10
- 84857355593
- Early use of cinacalcet (MIMPARA (R)/SENSIPAR (R)) in dialysis patients enables greatest achievement of NKF-KDOQI (TM) treatment targets for bone metabolism
- J.M. Frazao, P. Messa, J. Cunningham, P. Evenepoel, I. Shahapuni, and P. Urena Early use of cinacalcet (MIMPARA (R)/SENSIPAR (R)) in dialysis patients enables greatest achievement of NKF-KDOQI (TM) treatment targets for bone metabolism Nephrol Dial Transplant 21 2006 8 9
- (2006) Nephrol Dial Transplant , vol.21 , pp. 8-9
- Frazao, J.M.¹ Messa, P.² Cunningham, J.³ Evenepoel, P.⁴ Shahapuni, I.⁵ Urena, P.⁶

11
- 0141432172
- K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease
- K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201.
- (2003) Am J Kidney Dis. , vol.42 , Issue.4 SUPPL. 3

12
- 53049086973
- Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?
- M. Arenas, P. Rebollo, F. Alvarez-Ude, L. Prieto, M. Gil, and T. Malek [Is Cinacalcet a cost-effective treatment in severe secondary hyperparathyroidism in patients on hemodialysis?] Nefrologia 28 2008 511 516
- (2008) Nefrologia , vol.28 , pp. 511-516
- Arenas, M.¹ Rebollo, P.² Alvarez-Ude, F.³ Prieto, L.⁴ Gil, M.⁵ Malek, T.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.